← Back to Analyst Consensus 
STLN Buy
Starling Oncology, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 14, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 9, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jul 6, 2026 | Lake Street | initiate | — → Buy | — | 47% |
| Jun 17, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 8, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 13, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 55% |
| Mar 13, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 9, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 9, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
Price Target Trend
Aug 15, 2026 Latest: $9.4 Oct 23, 2026
EPS Estimates
0q $-0.05
Lo: $-0.07 Hi: $-0.04
5 analysts 0y $-0.16
Lo: $-0.21 Hi: $-0.11
5 analysts +1q $-0.01
Lo: $-0.04 Hi: $0.03
5 analysts ▲2
+1y $0.00
Lo: $-0.06 Hi: $0.10
4 analysts ▲3
Cross-Platform Signals
No cross-platform signals in the last 90 days